Stock Events

Stock Events

Leverage Shares 2X Long FIX Daily 

$4.35
67
+$0.48+12.4%Friday 20:53
+$0.05+1.15%00:12After hours

Statistics

Day High
4.61
Day Low
4.16
52W High
15.92
52W Low
3.83
Volume
7,844
Avg. Volume
6,680
Mkt Cap
129.5M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Expense Ratio

0.99%
0%
1%+
The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Earnings

Nov 4Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Q3 2026
-1.53
-1.11
-0.68
-0.26
Expected EPS
-0.326688
Actual EPS
-0.26

Financials

55.49%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
53.74MRevenue
29.82MNet Income

Analyst Ratings

$37.00Average Price Target
The highest estimate is ⁦66.00⁩.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FIXX. It's not an investment recommendation.
NVIDIA
8
NVDA
Intel
8
INTC
Realty Income
7
O
Alphabet
7
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is a leader in the development of gene-based therapies using CRISPR/Cas9 technology, directly competing with Homology's gene editing platform.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine operates in the gene editing space using CRISPR technology, similar to Homology Medicines, targeting genetic diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is another key player in CRISPR-based gene editing, competing in the same space as Homology Medicines for genetic disorder treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing in the genetic disease treatment market.
Regenxbio
RGNX
Mkt Cap475.29M
REGENXBIO is a biotechnology company focusing on the development, commercialization of gene therapies, directly competing with Homology's gene therapy approach.
Pfizer
PFE
Mkt Cap173.95B
Pfizer, through its acquisition of Bamboo Therapeutics and other initiatives, has entered the gene therapy space, making it a competitor in the broader market that Homology Medicines operates in.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, with its acquisition of Kite Pharma and focus on cell therapies, competes in the advanced therapy medicinal products space, including gene therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals, through its collaboration with CRISPR Therapeutics and focus on treating genetic diseases, competes in the same therapeutic areas as Homology Medicines.

Holdings

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Show More
CEO
Jodie Pope Morrison
Employees
22
Country
United States
ISIN
US88340G8015
WKN
000A4ZZ0Z

Listings

LSE
GB
0T6G.LSE
STU
DE
DB0.STU
XNAS
US
QTTB
MU
DE
35H.MU

0 Comments

Share your thoughts

FAQs

What is Leverage Shares 2X Long FIX Daily stock price today?▼
The current price of FIXX is $4.35 USD — it has increased by +12.4% in the past 24 hours. Watch Leverage Shares 2X Long FIX Daily stock price performance more closely on the chart.
What is Leverage Shares 2X Long FIX Daily stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on BATS exchange Leverage Shares 2X Long FIX Daily stocks are traded under the ticker FIXX.
What is Leverage Shares 2X Long FIX Daily market cap?▼
Today Leverage Shares 2X Long FIX Daily has the market capitalization of 129.5M
When is the next Leverage Shares 2X Long FIX Daily earnings date?▼
Leverage Shares 2X Long FIX Daily is going to release the next earnings report on March 16, 2027.
What were Leverage Shares 2X Long FIX Daily earnings last quarter?▼
FIXX earnings for the last quarter are -0.26 USD per share, whereas the estimation was -0.33 USD resulting in a +20.41% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Leverage Shares 2X Long FIX Daily revenue for the last year?▼
Leverage Shares 2X Long FIX Daily revenue for the last year amounts to 53.74M USD.
What is Leverage Shares 2X Long FIX Daily net income for the last year?▼
FIXX net income for the last year is 29.82M USD.
How many employees does Leverage Shares 2X Long FIX Daily have?▼
As of November 7, 2026, the company has 22 employees.
In which sector is Leverage Shares 2X Long FIX Daily located?▼
Leverage Shares 2X Long FIX Daily operates in the Health & Wellness sector.
When did Leverage Shares 2X Long FIX Daily complete a stock split?▼
The last stock split for Leverage Shares 2X Long FIX Daily was on March 26, 2024 with a ratio of 1:18.
Where is Leverage Shares 2X Long FIX Daily headquartered?▼
Leverage Shares 2X Long FIX Daily is headquartered in WALTHAM, United States.